Drug Royalty Corp., TPL Phytogen Inc., Peptide, Dura deal

DRI will provide C$1.5 million to further TPL's development of paclitaxel, a naturally occurring cancer compound found in the yew tree. In return, DRI (Toronto) will receive an undisclosed percentage of revenues from TPL (Delta, B.C.), including license fees, direct sales and royalties.

Separately, DRI said it will receive 12 percent of all monies received by partner PTD (Dee Why, Australia), as a result of the recent collaboration between PTD and Allergan Inc. (see BioCentury July 31). Allergan has an option to use GMDP, PTD's oral drug to treat skin disorders. ...